Policy & Regulation
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
18 November 2026 -

Swedish pharmaceutical company Dicot Pharma AB (Nasdaq First North:DICOT) announced on Wednesday that it has initiated the phase 2b clinical study of LIB-01, its investigational treatment for erectile dysfunction, following the first screening visit in the United States.

The study will evaluate the drug's efficacy at different doses following repeated monthly administration to support dose selection ahead of phase 3.

Three dose levels of LIB-01 are planned to be included in the study: 25 mg and 50 mg, which demonstrated proof-of-concept in phase 2a, as well as a higher dose to be determined in the first part of phase 2b. Part I is expected to be completed during the first quarter of 2027, followed by the initiation of part II.

Conducted in the United States and Europe, the adaptive trial will enrol at least 200 participants across all severities of erectile dysfunction.

Login
Username:

Password: